Abstract
The retinoblastoma tumour-suppressor protein (pRb) and p300/CBP co-activator proteins are important for control of proliferation and in tumour cells these are sequestered by viral oncoproteins such as E1A. pRb is involved in negatively regulating growth, and p300/CBP proteins have histone acetyltransferase (HAT) activity, which influences gene expression. Although it is known that phosphorylation by G1 cyclin-dependent kinases (CDKs) regulates pRb activity, the nature and role of other post-translational modifications is not understood. Here we identify acetylation as a new type of modification and level of control in pRb function. Adenovirus E1A, which binds p300/CBP through an amino-terminal transformation-sensitive domain, stimulates the acetylation of pRb by recruiting p300 and pRb into a multimeric-protein complex. Furthermore, pRb acetylation is under cell-cycle control, and acetylation hinders the phosphorylation of pRb by cyclin-dependent kinases. pRb binds more strongly when acetylated to the MDM2 oncoprotein, which indicates that acetylation may regulate protein–protein interactions in the pRb pathway. The acetylation of pRb defines a new level of cell-cycle control mediated by HAT. Furthermore, our results establish a relationship between p300, pRb and acetylation in which E1A acts to recruit and target a cellular HAT activity to pRb.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Weinberg, R. A. The retinoblastoma protein and cell control. Cell 81, 323–330 (1995).
Dyson, N. The regulation of E2F by pRB-family proteins. Genes Dev. 12, 2245–2262 (1998).
Sherr, C. J. Cancer cell cycles. Science 274, 1672–1677 (1996).
Shikama, N., Lyon, J. & La Thangue, N. B. The p300/CBP family: integrating signals with transcription factors and chromatin. Trends Cell Biol. 7, 230–236 (1997).
Goodman, R. H. & Smolik, S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 14, 1553–1577 (2000).
Hassig, C. A. & Schrieber, S. L. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr. Opin. 1, 300–308 (1997).
Brown, C. E., Lechner, T., Howe, L. & Workman, J. L. The many HATs of transcription co-activators. Trends Biol. Sci. 25, 15–18 (2000).
Gu, W. & Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595–606 (1997).
Sakaguchi, K. et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12, 2831–2841 (1998).
Martinez-Balbás, M. A., Bauer, U.-M., Nielsen, S. J., Brehm, A. & Kouzarides, T. Regulation of E2F-1 activity by acetylation. EMBO J. 19, 662–271 (2000).
Muraoka, M. et al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 12, 1565–1569 (1996).
Gayther, S. A. et al. Mutations truncating the EP300 acetylase in human cancers. Nature Genet. 24, 300–303 (2000).
Giles, R. H., Peters, D. J. & Bruening, M. H. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet. 14, 178–183 (1998).
Kung, A. L. et al. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev. 14, 272–277 (2000).
Dyson, N. & Harlow, E. Adenovirus E1A targets key regulators of cell proliferation. Cancer Surv. 12, 161–195 (1992).
Stein, R. W., Corrigan, M., Yaciul, P., Whelan, J. & Moran, E. Analysis of E1A-mediated growth regulation functions: binding of the p300-kilodalton cellular product correlates with E1A enhancer repression function and DNA synthesis-inducing activity. J. Virol. 64, 4421–4427 (1990).
Wang, H.-G. H., Moran, E. & Yacuik, P. E1A promotes association between p300 and pRB in multimeric complexes required for normal biological activity. J. Virol. 69, 7917–7924 (1995).
Yao, T.-P. et al. Gene dosage-dependent embryonic development and proliferation defects in micelacking the transcriptional integrator p300. Cell 93, 361–372 (1998).
Ait-Si-Ali, S. et al. CBP/p300 histone acetyltransferase activity is important for the G1/S transition. Oncogene 19, 2430–2437 (2000).
Ait-Si-Ali, S. et al. Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A. Nature 396, 184–186 (1998).
Bandara, L. R., Adamczewski, J. P., Hunt, T. & La Thangue, N. B. Cyclin A and the retinoblastoma gene product complex with a common transcription factor. Nature 352, 249–251 (1991).
Yang, X.-J., Ogryzko, V. V., Nishikawa, J.-I., Howard, B. H. & Nakatani, Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382, 319–324 (1996).
Arany, Z., Newsome, D., Oldread, E., Livingston, D. M. & Eckner, R. A family of transcriptional adaptor proteins targeted by the E1A oncoprotein. Nature 374, 81–84 (1995).
Kraus, V. B., Moran, E. & Nevins, J. R. Promoter-specific trans-activation by the adenovirus E1A12S product involves separate E1A domains. Mol. Cell. Biol. 12, 4391–4399 (1992).
Lassam, N. J., Bayley, S. T. & Graham, F. L. Tumor antigens of human Ad5 in transformed cells and in cells infected with transformation-defective host-range mutants. Cell 18, 781–791 (1979).
Xiao, Z.-X. et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375,964–698 (1995).
Adams, P. D. et al. Identification of a cyclin-Cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol. Cell. Biol. 16, 6623–6633 (1996).
Zhang, W., Bone, J. R., Edmondson, D. G., Turner, B. M. & Roth, S. Y. Essential and redundant functions of histone acetylation revealed by mutation of target lysines and loss of the Gcn5p acetyltransferase. EMBO J. 17, 3155–3167 (1998).
Zhang, Q., Yao, H., Vo, N. & Goodman, R. H. Acetylation of adenovirus E1A regulates binding of the transcriptional co-repressor CtBP. Proc. Natl Acad. Sci. USA 97, 14323–14328 (2000).
Zhang, W. & Bieker, J. J. Acetylation and modulation of erythroid Krüppel-like factor (EKLF) activity by interaction with histone acetyltransferases. Proc. Natl Acad. Sci. USA 95, 9855–9860 (1998).
Boyes, J., Byfield, P., Nakatani, Y. & Ogryzko, V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 396, 594–598 (1998).
Sartorelli, V. et al. Acetylation of MyoD directed by pCAF is necessary for the execution of the muscle program. Mol Cell. 4, 725–734 (1999).
Keirnan, R. et al. HIV-1 Tat transcriptional activity is regulated by acetylation. EMBO J. 18, 6106–6118 (1999).
Hseih, J. K. et al. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol. Cell 3, 181–193 (1999).
Lee, C.-W., Sørensen, T. S., Shikama, N. & La Thangue, N. B. Functional interplay between p53 and E2F through co-activator p300. Oncogene 16, 2695–2610 (1998).
Shikama, N. et al. A novel co-factor for p300 that regulates the p53 response. Mol. Cell 4, 365–376 (1999).
Ogryzko, V., Schiltz, R. L., Russanova, V., Howard, B. H. & Nakatani, Y. The transcriptional co-activators p300 and CBP are histone acetyltransferases. Cell 87, 953–959 (1996).
Morris, L., Allen, K. E. & La Thangue, N. B. Regulation of E2F transcription by cyclinE/Cdk2 kinase mediated through p300/CBP co-activators. Nature Cell Biol. 12, 232–239 (2000).
Loughran, Ö. & La Thangue, N. B. Apoptotic and growth-promoting activity of E2F modulated by MDM2. Mol. Cell Biol. 20, 2186–2197 (2000).
Shikama, N. et al. Functional interaction between nucleosome assembly proteins and p300/CREB-binding protein family co-activators. Mol. Cell Biol. 20, 8933–8943 (2000).
de la Luna, S., Allen, K. E., Mason, S. L. & La Thangue, N. B. Integration of a growth suppressing BTB/POZ domain protein with the DP component of the E2F transcription factor. EMBO J. 18, 212–228 (1999).
Acknowledgements
We thank P. Adams, L. Bandara, J. Gannon, B. Kaelin, S. Mittnacht and Y. Nakatani for providing reagents, L. Delavaine for His–E1A, M. Caldwell for assistance in preparing the manuscript, and the Medical Research Council, the Wellcome Trust, the Leukaemia Research Fund and European Union for supporting this research.
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Download plugins
Table S1 Numerical data for Fig. 5c (PDF 27 kb)
Table S2 Effect of p300 alone
Table S3 Examples of numerical data taken from other experiments
Rights and permissions
About this article
Cite this article
Chan, H., Krstic-Demonacos, M., Smith, L. et al. Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell Biol 3, 667–674 (2001). https://doi.org/10.1038/35083062
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/35083062
This article is cited by
-
Protein post-translational modifications in the regulation of cancer hallmarks
Cancer Gene Therapy (2023)
-
Post-translational modifications on the retinoblastoma protein
Journal of Biomedical Science (2022)
-
Tudor-domain protein PHF20L1 reads lysine methylated retinoblastoma tumour suppressor protein
Cell Death & Differentiation (2017)
-
Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy
Signal Transduction and Targeted Therapy (2016)
-
Epigenetic regulation of human retinoblastoma
Tumor Biology (2016)